Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma
- 17 April 2017
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 399, 1-9
- https://doi.org/10.1016/j.canlet.2017.04.012
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shanghai (17ZR1417800)
This publication has 37 references indexed in Scilit:
- Clusterin Protects Hepatocellular Carcinoma Cells from Endoplasmic Reticulum Stress Induced Apoptosis through GRP78PLOS ONE, 2013
- Melittin Suppresses VEGF-A-Induced Tumor Growth by Blocking VEGFR-2 and the COX-2-Mediated MAPK Signaling PathwayJournal of Natural Products, 2012
- Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivationJournal of Experimental & Clinical Cancer Research, 2012
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate PathwayCell, 2012
- Clusterin confers gmcitabine resistance in pancreatic cancerWorld Journal of Surgical Oncology, 2011
- Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohortEuropean Journal Of Cancer Prevention, 2010
- Identification of Clusterin Domain Involved in NF-κB Pathway RegulationPublished by Elsevier BV ,2010
- Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer CellsMolecular Cancer Research, 2010
- Serum total cholesterol and the risk of breast cancer in postmenopausal Korean womenCancer Causes & Control, 2009
- Regulation of CLU Gene Expression by Oncogenes and Epigenetic FactorsAdvances in Cancer Research, 2009